EP3790573A4 - Verfahren zur prophylaxe, verlangsamung des fortschreitens oder behandlung von zerebraler amyloidangiopathie, morbus alzheimer und / oder akutem schlaganfall - Google Patents

Verfahren zur prophylaxe, verlangsamung des fortschreitens oder behandlung von zerebraler amyloidangiopathie, morbus alzheimer und / oder akutem schlaganfall Download PDF

Info

Publication number
EP3790573A4
EP3790573A4 EP19799475.9A EP19799475A EP3790573A4 EP 3790573 A4 EP3790573 A4 EP 3790573A4 EP 19799475 A EP19799475 A EP 19799475A EP 3790573 A4 EP3790573 A4 EP 3790573A4
Authority
EP
European Patent Office
Prior art keywords
alzheimer
slowing
progression
disease
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19799475.9A
Other languages
English (en)
French (fr)
Other versions
EP3790573A1 (de
Inventor
Hollis Bryan BREWER Jr.
Michael M. MATIN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HDL Therapeutics Inc
Original Assignee
HDL Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by HDL Therapeutics Inc filed Critical HDL Therapeutics Inc
Publication of EP3790573A1 publication Critical patent/EP3790573A1/de
Publication of EP3790573A4 publication Critical patent/EP3790573A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19799475.9A 2018-05-11 2019-05-10 Verfahren zur prophylaxe, verlangsamung des fortschreitens oder behandlung von zerebraler amyloidangiopathie, morbus alzheimer und / oder akutem schlaganfall Withdrawn EP3790573A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862670615P 2018-05-11 2018-05-11
US201862700804P 2018-07-19 2018-07-19
PCT/US2019/031832 WO2019217897A1 (en) 2018-05-11 2019-05-10 Methods for prophylactically preventing, slowing the progression of, or treating cerebral amyloid angiopathy, alzheimer's disease and/or acute stroke

Publications (2)

Publication Number Publication Date
EP3790573A1 EP3790573A1 (de) 2021-03-17
EP3790573A4 true EP3790573A4 (de) 2022-05-11

Family

ID=68467552

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19799475.9A Withdrawn EP3790573A4 (de) 2018-05-11 2019-05-10 Verfahren zur prophylaxe, verlangsamung des fortschreitens oder behandlung von zerebraler amyloidangiopathie, morbus alzheimer und / oder akutem schlaganfall

Country Status (6)

Country Link
EP (1) EP3790573A4 (de)
JP (1) JP2021523182A (de)
CN (1) CN112384237A (de)
AU (1) AU2019264938A1 (de)
CA (1) CA3099999A1 (de)
WO (1) WO2019217897A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115414467B (zh) * 2022-10-14 2023-06-06 中国人民解放军陆军军医大学第二附属医院 载脂蛋白d在制备治疗脑出血药物中的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160868A1 (en) * 2017-03-01 2018-09-07 Hdl Therapeutics, Inc. Methods for prophylactically preventing, slowing the progression of, or treating alzheimer's disease
EP3589272A1 (de) * 2017-03-01 2020-01-08 HDL Therapeutics, Inc. Verfahren zur prophylaktischen prävention, verlangsamung der progression oder behandlung von morbus alzheimer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094191A2 (en) * 2001-05-23 2002-11-28 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
WO2004017946A1 (en) * 2002-08-26 2004-03-04 Lipid Sciences, Inc. Treating alzheimers using delipidated protein particles
ES2715496T3 (es) * 2003-07-03 2019-06-04 Hdl Therapeutics Inc Métodos y aparatos para crear derivados de partículas de HDL con un contenido reducido de lípidos
US8227408B2 (en) * 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
CA2761152A1 (en) * 2009-05-06 2010-11-11 Opko Curna, Llc Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160868A1 (en) * 2017-03-01 2018-09-07 Hdl Therapeutics, Inc. Methods for prophylactically preventing, slowing the progression of, or treating alzheimer's disease
EP3589272A1 (de) * 2017-03-01 2020-01-08 HDL Therapeutics, Inc. Verfahren zur prophylaktischen prävention, verlangsamung der progression oder behandlung von morbus alzheimer

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019217897A1 *
T. L. LEWIS ET AL: "Overexpression of Human Apolipoprotein A-I Preserves Cognitive Function and Attenuates Neuroinflammation and Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer Disease", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 47, 19 November 2010 (2010-11-19), pages 36958 - 36968, XP055191163, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.127829 *

Also Published As

Publication number Publication date
JP2021523182A (ja) 2021-09-02
AU2019264938A1 (en) 2020-12-03
CN112384237A (zh) 2021-02-19
WO2019217897A1 (en) 2019-11-14
CA3099999A1 (en) 2019-11-14
EP3790573A1 (de) 2021-03-17

Similar Documents

Publication Publication Date Title
DK3731772T3 (da) Systems for the treatment of disease states and disorders
EP3644996A4 (de) Verfahren zur behandlung von morbus huntington
EP3515505A4 (de) Aav-behandlung von morbus alzheimer
EP3645121A4 (de) Verfahren zur behandlung von morbus huntington
EP3698649A4 (de) Mittel zur vorbeugung oder linderung von morbus alzheimer
EP3458036A4 (de) Verfahren zur behandlung oder vorbeugung von morbus alzheimer und verwandten erkrankungen
EP3377118A4 (de) Verfahren zur behandlung von morbus alzheimer und zugehörigen erkrankungen
WO2017066712A3 (en) Modulators of telomere disease
IL280315A (en) Methods for treating and preventing Alzheimer's disease
EP3429598A4 (de) Zusammensetzungen und verfahren zur behandlung von beta-catenin-assoziierter erkrankung oder störung
EP3502248A4 (de) Antikörper gegen hmgb1 und zusammensetzung damit zur behandlung oder vorbeugung von morbus alzheimer
WO2017066796A3 (en) Modulators of telomere disease
EP3504204A4 (de) Indazolyl-l,2,4-thiadiazolamine und zugehörige verbindungen zur hemmung der rho-assoziierten proteinkinase und zur behandlung von krankheiten
WO2017044807A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
EP3261446A4 (de) Verfahren und zusammensetzungen zur behandlung oder prävention von morbus parkinson
EP3398614A4 (de) Mittel zur prävention und/oder behandlung von morbus alzheimer
EP3458045A4 (de) Behandlung der menière-krankheit
EP3746057A4 (de) Verfahren zur prävention oder behandlung von morbus alzheimer
EP3790573A4 (de) Verfahren zur prophylaxe, verlangsamung des fortschreitens oder behandlung von zerebraler amyloidangiopathie, morbus alzheimer und / oder akutem schlaganfall
EP3589272A4 (de) Verfahren zur prophylaktischen prävention, verlangsamung der progression oder behandlung von morbus alzheimer
EP3610879A4 (de) Zusammensetzung zur behandlung und/oder vorbeugung von alzheimer-krankheit
IL281395A (en) Treatment of early stages of Alzheimer's by replacing a small volume of plasma
EP3490546A4 (de) Verfahren zur behandlung oder prävention von amyloidbedingten bildgebungsanomalien im zusammenhang mit der behandlung von morbus alzheimer
EP3429569A4 (de) Verfahren zur vorbeugung oder behandlung der parkinson-krankheit durch die farnesylierung von paris
WO2020185651A3 (en) Compositions and methods for treating huntington's disease

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20201127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20220412

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/68 20060101ALI20220406BHEP

Ipc: A61P 25/28 20060101ALI20220406BHEP

Ipc: A61K 35/16 20150101ALI20220406BHEP

Ipc: A61K 38/17 20060101AFI20220406BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20221115